Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Capital Employed (2016 - 2025)

Cytosorbents (CTSO) has disclosed Return on Capital Employed for 13 consecutive years, with 0.38% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed rose 15.0% year-over-year to 0.38%, compared with a TTM value of 0.38% through Sep 2025, up 15.0%, and an annual FY2024 reading of 0.41%, up 31.0% over the prior year.
  • Return on Capital Employed was 0.38% for Q3 2025 at Cytosorbents, up from 0.44% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.14% in Q1 2021 and bottomed at 0.86% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.5%, with a median of 0.53% recorded in 2024.
  • The sharpest move saw Return on Capital Employed soared 57bps in 2021, then crashed -43bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.29% in 2021, then plummeted by -105bps to 0.59% in 2022, then plummeted by -44bps to 0.86% in 2023, then soared by 48bps to 0.44% in 2024, then increased by 14bps to 0.38% in 2025.
  • Business Quant data shows Return on Capital Employed for CTSO at 0.38% in Q3 2025, 0.44% in Q4 2024, and 0.53% in Q3 2024.